Bipartisan Bill Mandates Infant Formula Testing and FDA Reporting After Nine Deaths

The legislation follows a 2023 contamination event at a Michigan formula plant where bacterial growth led to nine infant deaths and sickened dozens more, triggering a nationwide recall and shortage. Lawmakers framed the measure as a preventive step to avoid future supply‑chain disruptions and protect infant health.

Key provisions require manufacturers to conduct routine Cronobacter and Salmonella testing on all formula before distribution, immediately notify the FDA of any detection, and follow FDA guidance on product disposal. The bill also mandates that the FDA issue a biennial progress report to Congress detailing compliance levels, any challenges faced, and recommendations for strengthening oversight.

Scientific evidence underscores the risk: a 2021 cohort study of 2,500 infants fed formula found that those exposed to Cronobacter had a higher observed rate of bloodstream infections—an association, not proven causation. A 2023 meta‑analysis of 12 case series reported an average mortality of roughly 20% among confirmed Cronobacter cases, highlighting the severity of infection when it occurs.

For parents, the rule means greater transparency about formula safety and a faster response if contamination is detected. Practically, caregivers should continue to follow preparation instructions, watch for symptoms such as fever or poor feeding, and consult a pediatrician if concerns arise.

Watch next for the FDA’s first progress report to Congress, expected within six months, and for any updates on industry compliance rates or changes in reported infection trends.